Caribou Biosciences (CRBU) Stock Forecast, Price Target & Predictions
CRBU Stock Forecast
Caribou Biosciences stock forecast is as follows: an average price target of $3.00 (represents a 41.51% upside from CRBU’s last price of $2.12) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
CRBU Price Target
The average price target for Caribou Biosciences (CRBU) is $3.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $3.00 to $3.00. This represents a potential 41.51% upside from CRBU's last price of $2.12.
CRBU Analyst Ratings
According to 3 Wall Street analysts, Caribou Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for CRBU stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Caribou Biosciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 03, 2024 | Liisa Bayko | Evercore ISI | $3.00 | $2.88 | 4.17% | 41.51% |
The latest Caribou Biosciences stock forecast, released on Jun 03, 2024 by Liisa Bayko from Evercore ISI, set a price target of $3.00, which represents a 4.17% increase from the stock price at the time of the forecast ($2.88), and a 41.51% increase from CRBU last price ($2.12).
Caribou Biosciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $3.00 |
| Last Closing Price | $2.12 | $2.12 | $2.12 |
| Upside/Downside | -100.00% | -100.00% | 41.51% |
In the current month, the average price target of Caribou Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Caribou Biosciences's last price of $2.12. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 04, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 14, 2024 | RBC Capital | Buy | Buy | Hold |
| Aug 14, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Jul 17, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jul 17, 2024 | Robert W. Baird | Underperform | Underperform | Hold |
| Jun 04, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 03, 2024 | Citigroup | Buy | Buy | Hold |
| May 16, 2024 | RBC Capital | Buy | Buy | Hold |
| May 16, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Feb 18, 2022 | RBC Capital | - | Outperform | Initialise |
Caribou Biosciences's last stock rating was published by H.C. Wainwright on Sep 04, 2024. The company gave CRBU a "Buy" rating, the same as its previous rate.
Caribou Biosciences Financial Forecast
Caribou Biosciences Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | $3.75M | $3.50M | $3.69M | $3.30M | - | $2.66M | $2.56M | $3.98M | $1.48M |
| Avg Forecast | $4.55M | $4.75M | $4.75M | $4.25M | $3.43M | $3.08M | $3.05M | $2.42M | $3.95M | $3.29M | $3.08M | $2.75M | $3.07M | $3.70M | $2.86M | $3.20M | $4.17M | $16.50M | $16.50M |
| High Forecast | $4.55M | $4.75M | $4.75M | $4.25M | $3.43M | $3.76M | $3.05M | $2.42M | $6.96M | $3.29M | $3.08M | $2.75M | $3.07M | $3.70M | $2.86M | $3.73M | $4.87M | $19.25M | $19.25M |
| Low Forecast | $4.55M | $4.75M | $4.75M | $4.25M | $3.43M | $2.28M | $3.05M | $2.42M | $2.68M | $3.29M | $3.08M | $2.75M | $3.07M | $3.70M | $2.86M | $2.67M | $3.48M | $13.75M | $13.75M |
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 1.22% | 1.27% | 1.20% | 0.89% | - | 0.83% | 0.61% | 0.24% | 0.09% |
Caribou Biosciences's average Quarter revenue forecast for Sep 23 based on 4 analysts is $3.29M, with a low forecast of $3.29M, and a high forecast of $3.29M. CRBU's average Quarter revenue forecast represents a -12.34% decrease compared to the company's last Quarter revenue of $3.75M (Jun 23).
Caribou Biosciences EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | $-32.87M | $-30.51M | $-30.52M | $-26.12M | - | $-20.46M | $-17.90M | $-20.71M | $-14.08M |
| Avg Forecast | $-4.55M | $-4.75M | $-4.75M | $-4.25M | $-3.43M | $-3.08M | $-3.05M | $-2.42M | $-3.95M | $-3.29M | $-3.08M | $-2.75M | $-3.07M | $-3.70M | $-2.86M | $-20.39M | $-4.17M | $-820.27M | $-16.50M |
| High Forecast | $-4.55M | $-4.75M | $-4.75M | $-4.25M | $-3.43M | $-2.28M | $-3.05M | $-2.42M | $-2.68M | $-3.29M | $-3.08M | $-2.75M | $-3.07M | $-3.70M | $-2.86M | $-16.31M | $-3.48M | $-656.22M | $-13.75M |
| Low Forecast | $-4.55M | $-4.75M | $-4.75M | $-4.25M | $-3.43M | $-3.76M | $-3.05M | $-2.42M | $-6.96M | $-3.29M | $-3.08M | $-2.75M | $-3.07M | $-3.70M | $-2.86M | $-24.47M | $-4.87M | $-984.33M | $-19.25M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 10.68% | 11.10% | 9.95% | 7.06% | - | 1.00% | 4.29% | 0.03% | 0.85% |
undefined analysts predict CRBU's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Caribou Biosciences's previous annual EBITDA (undefined) of $NaN.
Caribou Biosciences Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | - | - | $-29.52M | $-24.99M | $-26.99M | $-26.76M | - | $-17.32M | $-18.48M | $-20.97M | $-14.31M |
| Avg Forecast | $-50.59M | $-47.88M | $-44.72M | $-42.01M | $-41.33M | $-40.61M | $-41.37M | $-37.12M | $-33.20M | $-37.60M | $-44.71M | $-43.42M | $-41.70M | $-43.63M | $-32.44M | $-20.72M | $-31.63M | $-830.57M | $37.31M |
| High Forecast | $-50.59M | $-47.88M | $-44.72M | $-42.01M | $-41.33M | $-37.84M | $-41.37M | $-37.12M | $31.69M | $-37.60M | $-44.71M | $-43.42M | $-41.70M | $-43.63M | $-32.44M | $-16.58M | $-24.78M | $-664.46M | $45.39M |
| Low Forecast | $-50.59M | $-47.88M | $-44.72M | $-42.01M | $-41.33M | $-41.54M | $-41.37M | $-37.12M | $-66.41M | $-37.60M | $-44.71M | $-43.42M | $-41.70M | $-43.63M | $-32.44M | $-24.87M | $-38.49M | $-996.68M | $29.22M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.66% | 0.58% | 0.65% | 0.61% | - | 0.84% | 0.58% | 0.03% | -0.38% |
Caribou Biosciences's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CRBU's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Caribou Biosciences SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | - | - | $10.12M | $8.91M | $8.53M | $9.85M | - | $9.59M | $7.85M | $6.76M | $5.11M |
| Avg Forecast | $9.35M | $9.76M | $9.76M | $8.73M | $7.04M | $6.32M | $6.26M | $4.97M | $8.12M | $6.76M | $6.32M | $5.65M | $6.30M | $7.60M | $5.88M | $6.57M | $8.57M | $33.90M | $33.90M |
| High Forecast | $9.35M | $9.76M | $9.76M | $8.73M | $7.04M | $7.73M | $6.26M | $4.97M | $14.30M | $6.76M | $6.32M | $5.65M | $6.30M | $7.60M | $5.88M | $7.67M | $10.00M | $39.55M | $39.55M |
| Low Forecast | $9.35M | $9.76M | $9.76M | $8.73M | $7.04M | $4.69M | $6.26M | $4.97M | $5.50M | $6.76M | $6.32M | $5.65M | $6.30M | $7.60M | $5.88M | $5.48M | $7.14M | $28.25M | $28.25M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 1.60% | 1.58% | 1.35% | 1.30% | - | 1.46% | 0.92% | 0.20% | 0.15% |
Caribou Biosciences's average Quarter SG&A projection for Sep 23 is $6.76M, based on 4 Wall Street analysts, with a range of $6.76M to $6.76M. The forecast indicates a -33.17% fall compared to CRBU last annual SG&A of $10.12M (Jun 23).
Caribou Biosciences EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | - | - | $-0.48 | $-0.41 | $-0.44 | $-0.44 | - | $-0.29 | $-0.31 | $-0.46 | $-0.26 |
| Avg Forecast | $-0.56 | $-0.53 | $-0.49 | $-0.47 | $-0.46 | $-0.45 | $-0.46 | $-0.41 | $-0.37 | $-0.42 | $-0.49 | $-0.48 | $-0.46 | $-0.48 | $-0.36 | $-0.35 | $-0.36 | $-0.12 | $0.42 |
| High Forecast | $-0.56 | $-0.53 | $-0.49 | $-0.47 | $-0.46 | $-0.42 | $-0.46 | $-0.41 | $0.35 | $-0.42 | $-0.49 | $-0.48 | $-0.46 | $-0.48 | $-0.36 | $-0.27 | $-0.28 | $-0.09 | $0.51 |
| Low Forecast | $-0.56 | $-0.53 | $-0.49 | $-0.47 | $-0.46 | $-0.46 | $-0.46 | $-0.41 | $-0.74 | $-0.42 | $-0.49 | $-0.48 | $-0.46 | $-0.48 | $-0.36 | $-0.42 | $-0.44 | $-0.15 | $0.33 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.97% | 0.85% | 0.95% | 0.91% | - | 0.84% | 0.87% | 3.80% | -0.62% |
According to undefined Wall Street analysts, Caribou Biosciences's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CRBU previous annual EPS of $NaN (undefined).
Caribou Biosciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| FATE | Fate Therapeutics | $4.02 | $39.75 | 888.81% | Buy |
| NTLA | Intellia Therapeutics | $22.07 | $119.16 | 439.92% | Buy |
| EDIT | Editas Medicine | $3.95 | $17.00 | 330.38% | Buy |
| PRME | Prime Medicine | $4.09 | $17.25 | 321.76% | Buy |
| VERV | Verve Therapeutics | $5.50 | $21.50 | 290.91% | Buy |
| SANA | Sana Bio | $4.47 | $12.00 | 168.46% | Buy |
| ADPT | Adaptive Bio | $4.61 | $12.33 | 167.46% | Hold |
| BEAM | Beam Therapeutics | $26.30 | $64.20 | 144.11% | Buy |
| CRSP | CRISPR Therapeutics | $48.94 | $109.58 | 123.91% | Buy |
| CRBU | Caribou Biosciences | $2.12 | $3.00 | 41.51% | Buy |
CRBU Forecast FAQ
Is Caribou Biosciences a good buy?
Yes, according to 3 Wall Street analysts, Caribou Biosciences (CRBU) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of CRBU's total ratings.
What is CRBU's price target?
Caribou Biosciences (CRBU) average price target is $3 with a range of $3 to $3, implying a 41.51% from its last price of $2.12. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Caribou Biosciences stock go up soon?
According to Wall Street analysts' prediction for CRBU stock, the company can go up by 41.51% (from the last price of $2.12 to the average price target of $3), up by 41.51% based on the highest stock price target, and up by 41.51% based on the lowest stock price target.
Can Caribou Biosciences stock reach $3?
CRBU's average twelve months analyst stock price target of $3 does not support the claim that Caribou Biosciences can reach $3 in the near future.
What are Caribou Biosciences's analysts' financial forecasts?
Caribou Biosciences's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $11.97M (high $12.65M, low $11.17M), average EBITDA is $-11.968M (high $-11.174M, low $-12.653M), average net income is $-160M (high $-158M, low $-161M), average SG&A $24.59M (high $26M, low $22.96M), and average EPS is $-1.776 (high $-1.745, low $-1.786). CRBU's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $18.3M (high $18.3M, low $18.3M), average EBITDA is $-18.3M (high $-18.3M, low $-18.3M), average net income is $-185M (high $-185M, low $-185M), average SG&A $37.6M (high $37.6M, low $37.6M), and average EPS is $-2.05 (high $-2.05, low $-2.05).
Did the CRBU's actual financial results beat the analysts' financial forecasts?
Based on Caribou Biosciences's last annual report (Dec 2022), the company's revenue was $13.85M, beating the average analysts forecast of $12.83M by 7.97%. Apple's EBITDA was $-106M, beating the average prediction of $-30.018M by 254.01%. The company's net income was $-99.421M, missing the average estimation of $-138M by -28.21%. Apple's SG&A was $38.02M, beating the average forecast of $26.36M by 44.25%. Lastly, the company's EPS was $-1.64, missing the average prediction of $-1.653 by -0.80%. In terms of the last quarterly report (Jun 2023), Caribou Biosciences's revenue was $3.76M, beating the average analysts' forecast of $3.08M by 21.99%. The company's EBITDA was $-32.868M, beating the average prediction of $-3.078M by 967.84%. Caribou Biosciences's net income was $-29.519M, missing the average estimation of $-44.706M by -33.97%. The company's SG&A was $10.12M, beating the average forecast of $6.32M by 60.02%. Lastly, the company's EPS was $-0.48, missing the average prediction of $-0.495 by -3.00%